A survey found that Korea’s new drug reimbursement rate does not amount to the OECD average.

The Korean Research-based Pharmaceutical Industry Association (KRPIA, Chairman: Dong-Wook Oh) recently announced Korea’s new drug release status based on its ‘Global Access to New Medicines Report’

According to the report, it takes longer than the Organisation for Economic Co-operation and Development (OECD) country average for new drugs to be introduced to Korea after its global launch, and Korea’s release rate and reimbursement rate were also below the OECD country average.

The report was based on the ‘Pharmaceutical Research and Manufacturers of America’ report that was publi